-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Mendon insulin is a quick-acting human insulin similarity that lowers blood sugar by binding to insulin subjects on cells, stimulating glucose intake in skeletal muscles and adipose tissue and inhibiting the production of glucose in the liver.
not only for adults, adolescents and children with diabetes, but also for gestational diabetes.
, developed by NovoLog®®, its original drug, NovoLog®, was approved for listing in Europe in 1999, the United States in 2000 and domestic imports in 2002.
the company's launch, No® and Reed's sales have been on the rise, peaking at DKK 20.72 billion in 2015.
public data show that China's public medical institutions terminal winter insulin sales are also increasing year by year, and in 2018 the domestic sales of winter insulin close to 6.26 billion yuan, in 2018 China's public medical institutions terminal chemical insulin and similar drugs in the generic name TOP20, becoming one of the most competitive varieties of domestic pharmaceutical companies.
as the world's second largest insulin-like drug, after insulin glycelin.
Insight database shows that the insulin injections are currently approved, in addition to a number of enterprises in the study, including 3 companies reported for listing (see table below).
The Insight database shows that, in addition to mendon insulin, insulin injections are currently being carried out in phase 1 clinically.
In the field of sugar-lowering drugs, the main products are currently sunny diphthalate slow release tablets, naglina tablets, siglitin, etc. , in addition to Aglitin, Kaglie net research, coupled with the successive introduction of a number of insulin products, the future day sunny in the field of sugar reduction product line will be more abundant.
the original title: the field of force insulin, is a sunny day "mendong insulin injection" declared clinical.